Cellular reprogramming and the rise of rejuvenation biotech

João Pedro De Magalhães, Alejandro Ocampo

Research output: Contribution to journalShort surveypeer-review

Abstract

Cells can be rejuvenated and biological clocks reset using cellular reprogramming. A growing number of companies now aim to use cellular reprogramming to develop therapies for rejuvenating human beings. Can the ‘young’ science of rejuvenation, currently mostly based on in vitro studies, drive a new biotech field toward clinical applications?

Original languageEnglish
JournalTrends in Biotechnology
DOIs
Publication statusE-pub ahead of print - 18 Feb 2022
Externally publishedYes

Bibliographical note

Funding Information:
Work in the lab of J.P.M. is supported by grants from the Wellcome Trust (208375/Z/17/Z), LongeCity, and the Biotechnology and Biological Sciences Research Council (BB/R014949/1 and BB/V010123/1). J.P.M. is an advisor/consultant for the Longevity Vision Fund, Centaura, NOVOS, YouthBio Therapeutics and the founder of Magellan Science Ltd, a company providing consulting services in longevity science. A.O. is founder of Longevity Consultancy Group, a company providing consulting services in longevity science.

Publisher Copyright:
© 2022 Elsevier Ltd

Keywords

  • Yamanaka factors
  • aging
  • gene therapy
  • longevity

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering

Fingerprint

Dive into the research topics of 'Cellular reprogramming and the rise of rejuvenation biotech'. Together they form a unique fingerprint.

Cite this